Acceleron Pharma Cultura de la Empresa

Dr. Ravindra Kumar, also known as Ravi, Ph.D. has been the Chief Scientific Officer and Senior Vice President of Acceleron Pharma Inc. since January 2016. Dr. Kumar served as Vice President of Cell Biology & Bioanalytical Development at Acceleron Pharma Inc. and served as its Vice President until January 01, 2016. Dr. Kumar established and leads discovery research at Acceleron, including molecular and cell biology functions. Dr. Kumar has over 18 years of experience in protein and small molecule drug discovery. In 2005, he led the development, cell culture and quality control of Acceleron's GMP cell lines to support its first IND filing in March 2006. Dr. Kumar joined Acceleron Pharma as its First Scientist in March 2004. Prior to Acceleron, he worked for 12 years at Genetics Institute and Wyeth Pharmaceuticals. At Genetics Institute, Dr. Kumar was a key member of the Small Molecule Drug Discovery group and was responsible for the development of new expression cell lines/cell biology. Following the integration of discovery functions from Genetics Institute/GI and Wyeth Pharmaceuticals, Dr. Kumar led research to optimize protein expression in the Biological Chemistry group as a Senior Scientist. Dr. Kumar is the author of several key scientific manuscripts in the area of protein glycosylation and is named as an inventor of several patents. He holds a Ph.D. from University of New Brunswick, Canada. He holds BS in Chemistry from Rohilkhand University and MS in Chemistry from Meerut University. He completed his post-doctoral fellowship at Albert Einstein College of Medicine, in Bronx, NY.

Mr. Kevin F. McLaughlin serves as Training Consultant of John M. Campbell and Company Inc. Mr. McLaughlin has been Senior Vice President and Chief Financial Officer at Acceleron Pharma, Inc. since November 29, 2010 and serves as its Principal Accounting Officer. He has been a Treasurer of Acceleron Pharma Inc since January 2015. Mr. McLaughlin joined Acceleron in November 2010. He worked in the UK Chemical industry for 20 years prior to moving into the oil and gas production industry, where he has worked for more than 20 years. He has specialized knowledge and experience in water treatment associated with oil and gas production systems. For more than 15years he was manager of a group of technical specialists for a major Production Chemical Manufacturing company, with additional responsibility for product development, management and application in oil and gas production systems. He has traveled extensively to onshore and offshore locations throughout the Eastern Hemisphere solving water treatment and separation problems. He served as the Chief Financial Officer and Senior Vice President of Qteros, Inc. from October 2009 to 2010. Mr. McLaughlin Co-founded Aptius Education, Inc in 2007 and served as its Chief Operating Officer from 2007 to 2009. From March 1996 to August 1996, he served as the Vice President and Chief Financial Officer of Advanced Techcom, Inc. He served as Vice President of ventures and business support for BP's chemicals business based in Shanghai, China. From 1996 to 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He served as Treasurer and Senior Vice President of Praecis Pharmaceuticals Inc. since July 1998 and served as its Secretary since January 1997 and Chief Executive Officer since January 2005. He served as the Chief Operating Officer of Praecis Pharmaceuticals Inc. from September 7, 2004 to January 2005 and also served as its Chief Financial Officer since September 1996 and President since September 7, 2004. He served as Principal Accounting Officer and Executive Vice President of Praecis Pharmaceuticals Inc. From 1980 to 1996, he held senior level financial positions at Computervision Corporation and its predecessor Prime Computer, Inc., including Vice President, Treasurer and Director of Corporate Planning, where he was directly involved with financial, accounting and investor relations management, as well as public and private financing. He has been a Director at Stealth BioTherapeutics Incorporated since August 2017. He has been an Independent Director of Vericel Corporation since January 2015. He served as a Director of Praecis Pharmaceuticals Inc. since January 2005. He served as a Director of Aptius Education, Inc. from 2007 to 2009. He has developed and taught courses in oilfield water treatment since 1990. He is a Chartered Chemist, Member of the Royal Society of Chemistry, London, UK , and a member of SPE. Mr. McLaughlin holds B.S. in business administration and Accounting from Northeastern University and his MBA from Babson College.

Dr. Matthew L. Sherman, also known as Matt, M.D., has been the Chief Medical Officer and Executive Vice President of Acceleron Pharma, Inc. since October 2016. Dr. Sherman joined Acceleron in May 2006 and served as its Senior Vice President from May 2006 to March 2015. He served as the Chief Medical Officer and Senior Vice President of Synta Pharmaceuticals Corp. since March 2004, where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. He served as Head of Clinical Research and Regulatory Affairs at Synta Pharmaceuticals (now Madrigal Pharmaceuticals, Inc.). From October 1992 to January 1997, he held various clinical positions at Genetics Institute, which was acquired by Wyeth in January 1997. Dr. Sherman has extensive experience in developing drugs in oncology and other therapeutic areas. He has special knowledge of oncology and hematology drugs. From January 1997 to March 2004, Dr. Sherman worked at Wyeth, a global pharmaceutical and biotechnology company, in various capacities. He served as Wyeth Pharmaceutical's Assistant Vice President of Medical Research, Clinical Research and Development and Therapeutic Area Director for Oncology at Wyeth Research. Since 1998, Dr. Sherman provided senior Oncology and Hematology leadership at Wyeth for worldwide clinical development of 12 development projects for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg(R) by the FDA. Dr. Sherman started his career at Harvard Medical School, where he served as an Instructor of Medicine until 1989, an Assistant Professor of Medicine until 1992 and an Assistant Clinical Professor of Medicine until 2001 with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. He has been a Director of Pulmatrix, Inc. since September 2016. Dr. Sherman has published more than 75 original articles, expert reviews and editorials in numerous peer-reviewed journals on laboratory and clinical development of novel drugs as well as in clinical and molecular pharmacology and holds several patents and has contributed chapters to several books. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine at Georgetown University Medical Center. He completed his Clinical Fellowship training in Medicine and Medical Oncology at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute. He graduated Phi Beta Kappa from the Massachusetts Institute of Technology with a SB in Chemistry. Dr. Sherman received his M.D. degree with honors from Dartmouth Medical School.

Dr. Thomas P. Maniatis, also known as Tom, Ph.D., serves as a Science Partner of The Column Group LLC. Dr. Maniatis has been Professor and Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University College of Physicians and Surgeons since 2010. He co-founded ProScript Inc. He co-founded Acceleron Pharma Inc. in 2003 and served as its Chairman of Scientific Advisory Board from 2003 to 2016. He has been Member of Scientific Advisory Board and Member of the Board of Directors at Acceleron Pharma Inc. since 2003. He served as a Professor of Biochemistry and Molecular and Cellular Biology at Harvard University since 1981, where he studied the mechanisms of transcription and RNA splicing in eukaryotes. He served as a Scientific Advisor at Biogen Hemophilia Inc. He co-founded Genetics Institute, LLC, where he chaired the Science Advisory Board and served on the Board of Directors for over 17 years since 1980. He held faculty positions at the Cold Spring Harbor Laboratory and the California Institute of Technology. He was a pioneer in the development of gene cloning technology and has published extensively in the field of eukaryotic gene regulation. He serves as a Member of the United States National Academy of Sciences. He serves as Member of the Scientific Advisory Board for Alnara Pharmaceuticals, Inc. He served as a Director of Constellation Pharmaceuticals, Inc. and ProScript Inc. He served as a Member of Advisory Board at The Column Group LLC. He served as a Member of Scientific Advisory Board at Sirtris Pharmaceuticals, Inc. He co-authored the Molecular Cloning Manual, which was instrumental in the world-wide dissemination of the technology. The primary focus of his current research is to understand neurodegenerative disease mechanisms. He has received numerous awards for his research contributions, including the Eli Lilly Research Award in Microbiology and Immunology, the Richard Lounsbery Award for Biology and Medicine from the United States and French National Academies of Science and the Lasker-Koshland Special Achievement Award in Medical Science. Dr. Maniatis received a BA in Biology, an MS in Chemistry from the University of Colorado at Boulder and a Ph.D. in Molecular Biology from Vanderbilt University.

Ravi Kumar serves as the Senior Vice President and Chief Scientific Officer of Acceleron Pharma. Ravi started at Acceleron Pharma in January of 2012. Ravi is currently based in the Greater Boston Area.

Chris Rovaldi serves as the Senior Vice President, Program Management and Operations of Acceleron Pharma. Chris started at Acceleron Pharma in October of 2013. Chris is currently based in the Greater Boston Area.